

XRPD Pattern of Compound 1 Form I
Counts (x 1,000)
0
1
2
3
4
5
6
7
8
9
10
20
30
40
2Theta (Coupled TwoTheta/Theta) WL = 1.54060

FIG. 1



XRPD Pattern of Compound 1 Form II
Counts (x 1,000)
0
1
2
3
4
5
6
7
8
9
10
20
30
2Theta (Coupled TwoTheta/Theta) WL = 1.54060

FIG. 2



XRPD Pattern of Compound 1 Form III
Counts (x 100)
0 3 6 9 12 15 18 21 24 27 30
10 20 30 40
2Theta (Coupled TwoTheta/Theta) WL = 1.54060

FIG. 3



XRPD Pattern of Compound 1 Form IV
Counts (x 1,000)
0 1 2 3 4 5 6 7 8 9
10 20 30 40
2Theta (Coupled TwoTheta/Theta) WL = 1.54060

FIG. 4



XRPD Pattern of Compound 5 Form V
Counts (x 100)
0
2
4
6
8
10
12
14
10
20
30
40
2Theta (Coupled TwoTheta/Theta) WL = 1.54060

FIG. 5



XRPD Pattern of Compound 5 Form VI
Counts (x 100)
0
2
4
6
8
10
12
10
20
30
40
2Theta (Coupled TwoTheta/Theta) WL = 1.54060

FIG. 6



XRPD Pattern of Compound 5 Form VII
Counts (x 100)
0
2
4
6
8
10
12
14
16
18
10
20
30
40
2Theta (Coupled TwoTheta/Theta) WL = 1.54060

FIG. 7



XRPD Pattern of Compound 5 Form VIII
Counts (x 100)
0
2
4
6
8
10
12
14
10
20
30
40
2Theta (Coupled TwoTheta/Theta) WL = 1.54060

FIG. 8



XRPD Overlay of Compound 5 Form V, VI, VII and VIII
Counts (x 100)
0
3
6
9
12
15
18
21
24
27
10
20
30
40
2Theta (Coupled TwoTheta/Theta) WL = 1.54060
Form VIII
Form VII
Form VI
Form V

FIG. 9





Treatment Intervals
Response Assessment
End of Treatment
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Best IMWG Response:
SD
PD
0
4
8
12
16
20
Week

FIG. 10



Patient 4 received 50 µg for 8 days followed by 25 µg
Patient 5 received 25 µg Dose

FIG. 11



*Patient 4 received 50 µg for 8 days followed by 25 µg for 13 days followed by the regular 7-day rest period in cycle 1, subsequent cycles continued at 25µg 21 days on and 7 days off in a 28 -day cycle
Data not available for Patient 5

FIG. 12



Patient 2
% Degradation to baseline
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
5
10
15
20
Days
Ikaros
Aiolos
50 µg dosing

FIG. 13



Patient 4
% Degradation to baseline
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
5
10
15
20
Days
Ikaros
Aiolos
50 µg dosing
25 µg dosing

FIG. 14



Patient 5
% Degradation to baseline
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
0
5
10
15
Days
Ikaros
Aiolos
25 µg dosing

FIG. 15



0
-25
-50
-75
-100
Percent Change dFLC
0
5
10
15
20
Day 15 AUC0-24h (hr*ng/mL)
Patient 1
Patient 2
Patient 3

FIG. 16



Compound Concentration
Plasma (ng/mL) or Tumor (ng/g)
100
10
1
0.1
0
12
24
36
48
Hours
CC-92480 is not
detectable after 4 hours
Compound 1
DC80 (total)
CC-92480 (1000 μg/kg, Tumor)
Compound 1 (100 μg/kg, Tumor)
CC-92480 (1000 μg/kg, Plasma)
Compound 1 (100 μg/kg, Plasma)

FIG. 17



Percent of IKZF3 Remaining/
Normalized to GAPDH in NCI-H929 Tumors
100
50
0
0
12
24
36
48
Hours
Pomalidomide (3000 μg/kg)
Compound 1 (100 μg/kg)
CC-92480 (1000 μg/kg)

FIG. 18



QD Dosing
No Drug Administered
NCI-H929 tumor volume (mm3)
3000
2000
1000
0
0
7
14
21
28
35
42
49
56
63
Day
Vehicle (QD, PO)
Pomalidomide (3000 μg/kg, QD)
CC-92480 (1000 μg/kg, QD)
Compound 1 (100 μg/kg, QD)

FIG. 19



a. Vehicle 1, 5 µL/g, p.o., QD + Vehicle 2, 10 µL/g, i.v., QW
b. Compd. 1, 0.01 mg/kg, p.o., QD
c. Ibrutinib, 12.5 mg/kg, p.o., QD
d. Ibrutinib, 25 mg/kg, p.o., QD
e. Rituximab, 10 mg/kg, i.v., QW
f. Rituximab, 30 mg/kg, i.v., QW
g. Compd. 1, 0.01 mg/kg, p.o., QD + Ibrutinib, 12.5 mg/kg, p.o., QD
h. Compd. 1, 0.01 mg/kg, p.o., QD + Ibrutinib, 25 mg/kg, p.o., QD
i. Compd. 1, 0.01 mg/kg, p.o., QD + Rituximab, 10 mg/kg, i.v., QW
j. Compd. 1, 0.01 mg/kg, p.o., QD + Rituximab, 30 mg/kg, i.v., QW
Body weight (g)
35
30
25
20
15
0
7
14
21
28
35
42
Days after the start of treatment

FIG. 20



a. Vehicle 1, 5 µL/g, p.o., QD + Vehicle 2, 10 µL/g, i.v., QW
b. Compd. 1, 0.01 mg/kg, p.o., QD
c. Ibrutinib, 12.5 mg/kg, p.o., QD
d. Ibrutinib, 25 mg/kg, p.o., QD
e. Rituximab, 10 mg/kg, i.v., QW
f. Rituximab, 30 mg/kg, i.v., QW
g. Compd. 1, 0.01 mg/kg, p.o., QD + Ibrutinib, 12.5 mg/kg, p.o., QD
h. Compd. 1, 0.01 mg/kg, p.o., QD + Ibrutinib, 25 mg/kg, p.o., QD
i. Compd. 1, 0.01 mg/kg, p.o., QD + Rituximab, 10 mg/kg, i.v., QW
j. Compd. 1, 0.01 mg/kg, p.o., QD + Rituximab, 30 mg/kg, i.v., QW
% Body weight change
50
30
10
-10
-30
0
7
14
21
28
35
42
Days after the start of treatment

FIG. 21



Vehicle
Ibrutinib (25 mg/kg, QD)
Cmpd. 1 (10 μg/kg, QD)
Combo
Percent survival
100
50
0
0
7
14
21
28
35
42
Days elapsed

FIG. 22